Aida Pharmaceuticals Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Biao Jin

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	18.9yrs
CEO ownership	n/a
Management average tenure	18.9yrs
Board average tenure	19.1yrs

Recent management updates

No updates

Recent updates

No updates

CEO

Biao Jin (76 yo)

18.9yrs

Tenure

US$19,056

Compensation

Mr. Biao Jin serves as Chairman and Chief Executive Officer at Aida Pharmaceuticals, Inc. Mr. Jin serves as Chief Executive Officer at Jiangsu Institute Of Microbiology Co., Ltd. He serves as the Chairman...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Biao Jin	Chairman and Chief Executive Officer	18.9yrs	US$19.06k	no data
Lin Hui	Chief Financial Officer and Principal Accounting Officer	19.1yrs	US$12.70k	no data
Yue Jiang	Chief of Investment Department and Secretary	18.4yrs	no data	no data
Qiu Jiajun	Member of Compensation Committee and Director	no data	no data	no data

18.9yrs

Average Tenure

58yo

Average Age

Experienced Management: AIDA's management team is seasoned and experienced (18.9 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Biao Jin	Chairman and Chief Executive Officer	19.1yrs	US$19.06k	no data
Qiu Jiajun	Member of Compensation Committee and Director	19.1yrs	no data	no data
Qiong Zhang	Director	19.1yrs	no data	no data

19.1yrs

Average Tenure

58yo

Average Age

Experienced Board: AIDA's board of directors are seasoned and experienced ( 19.1 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/11 04:25
End of Day Share Price	2024/12/18 00:00
Earnings	2008/09/30
Annual Earnings	2007/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aida Pharmaceuticals, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution